Dapagliflozin May Benefit Hospitalized COVID-19 Patients


Because COVID-19 affects multiple organ systems, Hiddo Lambers Heerspink, Ph.D., PharmD, and his colleagues conducted a secondary analysis of the Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19) trial to assess the efficacy and safety of the SGLT2 inhibitor dapagliflozin in 1,250 patients with cardio-metabolic risk factors acutely hospitalized with COVID-19.

Dapagliflozin was well-tolerated regardless of patients’ kidney function but compared with placebo, it did not result in a significant risk reduction in the primary outcomes of organ dysfunction or death, or improvement in recovery

.

Dapagliflozin also did not result in a significant risk reduction in the secondary composite kidney outcome of a composite acute kidney injury, kidney replacement therapy, or death.

These new data from DARE-19 reinforce the safety of dapagliflozin in acutely ill patients hospitalized with COVID-19 even in those with reduced kidney function who are at particularly high risk of acute kidney injury,” said Dr. Heerspink.

An accompanying editorial notes that DARE-19 was a neutral trial for all of the outcomes it assessed, both individually and collectively.

Nevertheless, DARE-19 was a positive trial from the perspective of the safety of using an SGLT2 inhibitor while experiencing acute illness in patients with either preserved or reduced kidney function,” the authors wrote.

Source: Medindia

Source link

Home Remedies

%d bloggers like this: